Johnson & Johnson has said that it is planning to exit Kenvue, the consumer health business it spun out in 2022. The sale could be worth about $3.75bn, according to reports. J&J is focusing on its pharmaceutical and medical devises business.
Join our network of executives who receive the MBS News daily, as well as the insights, analysis and our weekly column in The Weekend Edition.
You’ll be able to unsubscribe at any time.